Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Romeo who wrote (5499)	10/14/1998 8:13:00 PM
From: nord	of 6136

We have known for some time that a rebounding number of cd4 cells on HAART does not equate to the same number of cd4 cells on the way down. ie once the stem cell population is hampered the ability to mount a specific T cell response was hampered despite rising T cells. The answer to keeping hiv at bay is liklely multifactorial. ideally shutting off viral replication to prevent emergence of drug resistant mutants and ideally to restore the funtion of the damaged stem cell population. It is clear we have potent drugs that offer the promise of shutting down the viral replication. Durability is now the qwuestion. ie how long can we keep it suppressed? If the imnr drug does what we hope it may be able to stimulate the T stem cell population to boost host immunity thus tipping the balance in favor of the patient. If this form of adjuvant immune stimulation works we may be able to see pwa live a normal lifespan with relatively few side effects. Time will tell and soon the data will give us the first glance at what may be the next big breakthrough in anti retroviral and now immune restorative funtion. let 's all hope it works for all those who live each day with hiv

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next